Why These 5 Stocks Are on The Move on Monday

4. AstraZeneca PLC (NASDAQ:AZN) shares are up over 4% despite the broader market weakness after the company reported interim analysis of a phase 3 trail around Enhertu. According to AstraZeneca PLC (NASDAQ:AZN)’s trial data, “Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer”.

Executive Vice President of Oncology R&D at AstraZeneca PLC (NASDAQ:AZN), Susan Galbraith, also said of the results, “Today’s results are ground-breaking. Enhertu tripled progression-free survival as assessed by investigators, and provided a disease control rate exceeding 95% compared to 77% for T-DM1 in DESTINY-Breast03.”

Raiv Jain‘s Raiv Jain owned 16,632,033 shares in AstraZeneca PLC (NASDAQ:AZN) at the end of June 30.